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Katja Thomas1, Hagen Schrötter2, Michael Halank3 and Tjalf Ziemssen1*Abstract
Background: Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting
multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in
organism including immune system and cardiovascular system clinical monitoring of patients and evaluation of
adverse events are recommended. Despite extensive data on cardiovascular safety, experience with fingolimod in
patients with concomitant cardiological disease, especially within the pulmonary circulation, is rare.
Case presentation: We report the case of a 46-year-old woman presented with relapsing remitting multiple
sclerosis and severe idiopathic pulmonary arterial hypertension. Fingolimod was initiated because of disease activity
of multiple sclerosis with two relapses and gadolinium-enhancing lesions in MRI. The patient demonstrated stable
disease course of idiopathic pulmonary arterial hypertension when fingolimod was started. Fingolimod therapy did
not alter or even worsen the pulmonary or cardiovascular conditions during first dose application as well as follow
up of nine months.
Conclusion: In this report, we present the first case of fingolimod treatment in a patient with highly active multiple
sclerosis and severe idiopathic pulmonary arterial hypertension. We suggest an interdisciplinary approach with
detailed cardiopulmonary monitoring for safety in such patients.
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Fingolimod is approved as second line disease modifying
drug for highly active relapsing remitting multiple scler-
osis (MS) patients. In its phosphorylated form it serves
as sphingosine-1-phosphat (S1P) receptor analogue, or-
chestrating relevant mechanisms in the immune system
but also cardiovascular system [1]. There are only few
reports on S1P-triggered effects on cardiovascular func-
tion within systemic or pulmonary circulation.Case presentation
The 46-year-old female patient was diagnosed with
relapsing-remitting MS in 2005. She started on interferon-
beta 1a in 2005 presenting a stable disease course in the* Correspondence: Tjalf.Ziemssen@uniklinikum-dresden.de
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unless otherwise stated.following years. In 2010, severe idiopathic pulmonary ar-
terial hypertension (IPAH) and one-vessel coronary artery
disease were diagnosed after progressive exertional dys-
pnea, dizziness, marked restricted physical performance
and mild stenocardia since 10 months, characterizing
heart failure stage III of classification of the New York
Heart Association (NYHA). Echocardiography showed
right ventricular hypertrophy, moderate reduction of left
ventricular and severe reduction of right ventricular func-
tion, paradox septum deviation and severe tricuspid valve
insufficiency with an estimated systolic pressure of
90 mmHg (Table 1). Routine echocardiography 12 months
before was without abnormal results. Combined left and
right heart catheterization demonstrated one-vessel coron-
ary artery disease and severe pre-capillary pulmonary
hypertension with a mean pulmonary arterial pressure of
66 mmHg (normal: 10–20 mmHg), left ventricular end-
diastolic pressure of 12 mmHg (normal: 3–12 mmHg),
cardiac index of 1.5 L/min/m2 (normal: 2.5-4.0 L/min/m2)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Right and left ventricular parameter before and after fingolimod application
Diagnosed PAH Pre-FTY Post-FTY 1 month 3 month follow up 9 month follow up
NYHA III II II II II
HR [bpm] 80 77 65 60 68
BP [mmHg] 120/88 130/80 110/90 122/85 125/85
RVESP [mmHg] 90 70 65 n.d. 55
TAPSE [mm] 13 21 n.d. n.d. 20
Right ventricle hypertrophy mild mild mild n.d. mild
LV EF 45% 60% 60% n.d. 60%
NT-proBNP [pmol/L] 207 17 16 15 11
pH (cap.) 7.46 7.54 7.52 7.47 7.43
PO2 (cap.) [kPa] 12.3 10.1 11.7 10.4 10.4
PCO2 (cap.) [kPa] 3.9 4.6 3.5 4.6 4,72
Respiratory resistance Normal Normal Normal Normal Normal
Obstructive ventilation Normal Normal Normal Normal Normal
Restrictive ventilation Normal Normal Normal Normal Normal
Diffusion respiration TLCO SB 49% TLCO SB 51% TLCO SB 53% TLCO SB 50% TLCO SB 49%
FTY, Fingolimod; n.d., not done. Reference values: RVESP: 15–30 mmHg; TAPSE: < 20 mm; LV-EF, left ventricular ejection fraction: 50–70%; NT-proBNP: ≤ 17
pmol/L, pH (capillary): 7.35-7.45; PO2 (capillary), partial pressure of oxygen: 11.1-14.4 kPa; PCO2 (capillary), partial pressure of carbon dioxide: 4.27-6.4 kPa;
TLCO SB, transfer coefficient of lung for carbon monoxide: > 60%.
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mal: 0.25-1.6 wood units). The initial level of N-terminal
pro-hormone of brain natriuretic peptide (NT-proBNP)
presented with an increase up to 207 pmol/L (normal: ≤17
pmol/L). One week after placing a drug eluding stent in
the left main coronary artery (LMCA) control echocardi-
ography revealed an unchanged severe pulmonary hyper-
tension with near normalized left ventricular function.
Diagnosis of severe IPAH was established by exclusion of
other causes of pulmonary hypertension according to the
diagnostic criteria reported by Galie et al. [2]. Compression
of the LMCA by an enlarged pulmonary artery was
excluded by CT-angiography of the pulmonary arteries.
The patient started on the endothelin receptor antagonist
ambrisentan and phosphodiesterase inhibitor tadalafil. By
this treatment, the patient reported an improvement of
physical performance, no more dizziness and stenocardiaTable 2 Parameter of systemic circulation during passive orth
Pre-FTY baseline 2 h post-FTY 4 h post-FTY
→ ↑ → → ↑ → → ↑
HR [bpm] 74 84 80 70 73 66 61 64
Psyst [mmHg] 143 130 156 123 108 129 134 114
Pdiast [mmHg] 85 82 92 65 65 72 71 67
TPR [mmHg *s/ml] 1.43 1.55 1.5 0.68 0.76 0.83 0.92 0.86
CO [lpm] 3.9 3.5 4.3 8.4 5.9 6.9 6.7 6.3
SV |ml] 50 43 54 119 83 67 106 97
E/I 1.16 1.13 1.14
FTY, Fingolimod. → lying position; ↑ tilted position. Reference values: HR: 60–100 b
pressure: 60–90 mmHg; TPR, total peripheral resistance: 0.6-1.3 mmHg*s/ml; CO, caras well as a stable disease course corresponding to heart
failure of stage NYHA II. In further evaluations, mild right
ventricular hypertrophy and insufficiency, mild tricuspid
valve insufficiency, decrease of right ventricular-systolic
pressure in echocardiography, normal lung function, mild
impairment in diffusion capacity of carbon monoxide and
mild hypocapnia was detectable in the following years
(Table 1).
In 2013, she demonstrated with significant clinical
disease activity of MS with two relapses and MRI activity
with three gadolinium-enhancing lesions and an Ex-
panded Disability Status Scale (EDSS) of 4.0. Because of
positive JC-virus serology, fingolimod was selected as
second line treatment. Before first dose application,
extensive cardio-pulmonary testing demonstrated stable
cardiovascular parameters as described above (Table 1).
The baseline electrocardiogram (ECG) showed a sinusostatic tilt test before and after fingolimod application
6 h post-FTY 3 month follow-up 9 month follow-up
→ → ↑ → → ↑ → → ↑ →
59 74 76 74 65 70 65 60 64 62
133 127 118 134 156 126 131 149 127 136
72 68 70 75 74 72 71 77 75 77
0.9 0.69 0.88 0.85 0.81 1.06 0.93 1.1 1.41 1.23
6.5 7.9 6.1 7.1 7.4 4.9 6.2 5.9 4.5 5.1
116 109 78 103 116 72 96 102 70 83
1.16 1.06 1.09
pm; Psyst, systolic blood pressure: 100–140 mmHg; Pdiast, diastolic blood
diac output: 4–8 lpm; SV, stroke volume: 55–100 ml; E/I: > 1.11.
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dose, heart rate (HR) decreased at maximum by 13 bpm
at 4 hours and reached baseline HR 6 hours after initial
fingolimod administration. 12 lead ECG as well as
Holter ECG did not demonstrate any significant abnor-
malities (Table 2). Blood pressure (BP) in lying and tilted
up position presented within normal range during the
whole 6 hours monitoring (Table 2). The patient did not
complain any findings in the first 6 hours after fingoli-
mod application. Cardio-pulmonary testing one week,
one, three and nine months after first dose application
demonstrated stable parameters in ECG, BP, echocardi-
ography, body plethysmography and blood gas analy-
sis (Table 1). Especially relevant parameters of right
ventricular and pulmonary circulation including right
ventricular hypertrophy, right ventricular end-systolic
pressure (RVESP), right-ventricular ejection fraction and
tricuspid annular plane systolic excursion (TAPSE) kept
stable on fingolimod treatment (Table 1). Detailed test-
ing of the autonomic nervous system demonstrated
no change of the efferent sympathetic regulation and
left ventricular function after orthostatic stress before,
2 hours, 4 hours, and 6 hours after fingolimod first dose
application as well as in three and nine month follow up
(Table 2). Maximal heart rate variability measured by
expiration/inspiration quotient (E/I) during deep metro-
nomic breathing showed a decrease to 1.06, which stabi-
lized over time back to 1.09 (Table 2) [3]. There were no
additional cardiac or pulmonary symptoms than known
before fingolimod treatment.
Conclusion
In this report, we present the first case of fingolimod
treatment in a patient with severe IPAH and coronary
heart disease. Although there were no short- and long-
term side effects by fingolimod in this patient, patients
with cardiovascular disease should be carefully selected
for fingolimod therapy. It is necessary to evaluate exist-
ing cardiovascular conditions inclusive the medication
critically. An interdisciplinary approach with frequent
cardio-pulmonary exams like ECG, BP, echocardiog-
raphy, body plethysmography and blood gas analysis
should be complemented to monitor and ensure safety
in such patients.
Fingolimod is known as S1P receptor analogue that
mediates inhibition of lymphocyte egress from lymph
nodes into the peripheral blood [1]. Beside the immune
system S1P receptors are also relevant for further
signallining inside the human body including the cardio-
vascular and pulmonary system. Based on the natural
distribution pattern of S1P receptors especially on artrial
myocytes, fingolimod can cause transient bradycardia or
decrease of atrioventricular conduction [4]. It is known,
that S1P promotes contraction of bronchi and especiallybronchial smooth muscle cells [5,6]. Furthermore in-
creased risk of arterial hypertension and vascular dysfunc-
tion caused by S1P receptor subtypes in endothelium and
smooth muscle cell layer is discussed during fingolimod
treatment [7,8]. Today, there is extensive experience re-
garding safety and tolerability during first dose application
and long-term treatment with fingolimod in MS patients
[9]. Several fingolimod-related cardiovascular side effects
have been discussed so far including prolonged symptom-
atic bradycardia, AV block or non-fatal cardiac asystole
at first dose application or ventricular arrhythmia after
five months of treatment [10-12]. A critical arterial
vasospasm of the left arm seven days after initiation
of fingolimod was also presented [13]. In a patient
with Wolff-Parkinson-White syndrome, no cardiovascular
interaction with fingolimod was described [14]. Neverthe-
less, data on fingolimod treated patients with definite
concomitant cardiac diseases are rare, especially if the
right side of the heart is involved.
IPAH is characterized by elevated pulmonary arterial
pressure and pulmonary vascular resistance causing right
ventricular hypertrophy and insufficiency. Early inter-
vention is necessary to avoid right heart failure and
sudden death. In our case, symptoms and objective as-
sessment associated with IPAH improved after treatment
initiation. Fingolimod was started during a stabilized dis-
ease course of IPAH over two years. Fingolimod therapy
did not alter or even worsen the pulmonary or cardio-
vascular conditions during first dose application as well
as during follow up.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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